医薬品受託製造市場 – 2030年までの世界予測

Pharmaceutical Contract Manufacturing Market - Global Forecast To 2030

医薬品受託製造市場 - サービス [医薬品開発、医薬品（API、FDF - 非経口、錠剤、カプセル）、生物製剤（API、FDF）、包装およびラベリング、充填・仕上げ）、分子（小分子、大分子（ADC、CGT）] - 2030年までの世界予測

Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule), Biologics (API, FDF), Packaging & Labelling, Fill-finish), Molecule (Small, Large (ADC, CGT)) - Global Forecast to 2030

商品番号 : SMB-7768

出版社	MarketsandMarkets
出版年月	2025年8月
ページ数	522
図表数	683
価格タイプ	シングルユーザライセンス
価格	USD 4,950
種別	英文調査報告書

この調査レポートでは、医薬品受託製造市場を、サービス別（医薬品開発サービス、医薬品製造サービス［医薬品API製造サービス、医薬品FDF製造サービス（非経口剤、錠剤、カプセル剤、経口液剤、半固形剤、その他の製剤）、生物製剤製造サービス（生物製剤API製造サービス、生物製剤FDF製造サービス）］、包装およびラベリングサービス、充填・仕上げサービス、その他のサービス］、分子別（低分子（高効力低分子、オリゴヌクレオチドおよび合成ペプチド、放射性医薬品、およびその他の分子）、高分子（mAbs、CGT、ADC、ワクチン、治療用ペプチドおよびタンパク質、およびその他の高分子））およびエンドユーザー別（大手製薬会社、中小製薬会社、ジェネリック医薬品会社、その他のエンドユーザー）、および地域別（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）に分類しています。本レポートは、医薬品受託製造市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーの詳細な分析により、事業概要、ソリューション、主要戦略、協業、パートナーシップ、契約に関する洞察を提供しています。医薬品受託製造市場に関連する新製品の発売、協業、買収、最近の動向についても解説しています。

本レポートは、医薬品受託製造市場全体とそのサブセグメントの収益数値の近似値を提供することで、市場リーダー企業と新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、事業のポジショニングを改善し、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。

世界の医薬品受託製造市場は、2025年の推定2,099億米ドルから2030年には3,119億5,000万米ドルに達し、2025年から2030年にかけて年平均成長率（CAGR）8.2%で成長すると予測されています。医薬品受託製造市場の拡大は、主にGLP-1の製造・開発、ADCの承認取得・プログラム、そして大型バイオ医薬品の独占権切れに伴うアウトソーシングによって牽引されてきました。しかしながら、製薬企業による自社生産能力の拡大や、欧米における価格圧力が市場の成長を抑制すると予想されます。

The global pharmaceutical contract manufacturing market is projected to reach USD 311.95 billion by 2030 from an estimated USD 209.90 billion in 2025, at a CAGR of 8.2% from 2025 to 2030. The expansion of the pharmaceutical contract manufacturing market has been predominantly fueled by outsourcing for GLP-1 manufacturing & development, ADC approvals and programs, and loss of exclusivity for blockbuster biologics. However, expansion of in-house capacities by pharmaceutical companies and pricing pressure in the US and Europe are expected to restrict market growth.

医薬品受託製造市場 - 2030年までの世界予測 — pharmaceutical-contract-manufacturing-market-Overview

The biologics FDF manufacturing services segment reported the highest CAGR in 2024.

Based on biologics manufacturing service, the pharmaceutical contract manufacturing market is segmented into biologics API manufacturing services and biologics FDF Manufacturing Services. Among these, biologics FDF manufacturing services are projected to experience the fastest growth rate during the forecast period from 2025 to 2030. This strong growth outlook is primarily driven by the surging demand for biologics, which include complex and high-value products such as monoclonal antibodies, recombinant proteins, cell and gene therapies, and vaccines. The rising focus on targeted pharmacological therapies, which offer greater efficacy and reduced side effects compared to traditional treatments, is further boosting demand for specialized manufacturing capabilities. In addition, the increasing volume of research and development activities, particularly in cell and gene therapy, contributes significantly to market expansion. A growing number of pipeline candidates in these advanced therapeutic areas requires highly specialized manufacturing processes, encouraging pharmaceutical companies to partner with CDMOs possessing the necessary expertise, infrastructure, and regulatory compliance. This trend is expected to result in higher investment in advanced biologics production technologies, capacity expansion, and quality systems within CDMOs. Consequently, the FDF manufacturing services segment is well-positioned to achieve substantial growth and play an increasingly critical role in the pharmaceutical outsourcing landscape over the coming years.

The small molecules segment dominated the pharmaceutical contract manufacturing market in 2024.

The pharmaceutical contract manufacturing market is segmented by molecules into small molecules & large molecules. In 2024, small molecules, encompassing high-potency small molecules, oligonucleotides and synthetic peptides, radiopharmaceuticals, and other small molecules, hold the largest share of the pharmaceutical CDMO market by molecule segment. High-potency small molecules, particularly oncology, require specialized containment and expertise, driving demand for CDMOs with advanced facilities. Oligonucleotides and synthetic peptides have gained momentum due to their role in precision medicine and targeted therapies, offering new outsourcing opportunities. Radiopharmaceuticals, with applications in diagnostics and treatment, are seeing increased interest as nuclear medicine expands. The other small molecules category remains vital for numerous therapeutic areas, from cardiovascular to infectious diseases. Small molecules are favored for their stability, oral bioavailability, and cost-efficient mass production, making them attractive for both innovative and generic drug pipelines. The growing prevalence of chronic conditions, coupled with ongoing innovation in synthetic chemistry and continuous manufacturing, strengthens their market position. CDMOs with specialized expertise across these subcategories can leverage strong demand from pharmaceutical companies seeking speed, flexibility, and cost efficiency, ensuring that small molecules continue to be a core driver of the CDMO industry’s growth.

医薬品受託製造市場 - 2030年までの世界予測 region — pharmaceutical-contract-manufacturing-market-Region

North America accounted for the largest share in the global pharmaceutical contract manufacturing market from 2025 to 2030.

North America dominated the pharmaceutical CDMO market in 2024, driven by its strong regulatory framework, advanced manufacturing infrastructure, and high concentration of leading CDMO players. The region benefits from a well-established pharmaceutical industry, extensive R&D capabilities, and a strong presence of big pharmaceutical companies outsourcing development and manufacturing to optimize costs and speed to market. Supportive regulatory agencies, particularly the US FDA, promote innovation through clear guidelines and expedited approvals, encouraging investment in advanced manufacturing technologies such as continuous processing and high-potency API production. North America also leads in biologics and advanced therapies manufacturing, supported by specialized CDMO facilities catering to cell and gene therapies. Strategic collaborations, mergers, and acquisitions further enhance service portfolios and capacity. The region’s robust venture capital ecosystem and academic-industry partnerships foster innovation, while its focus on quality, compliance, and scalability attracts global clients.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side- 30%
By Designation: Managers- 45%, CXO and Directors- 30%, and Executives- 25%
By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5%

Key Companies

Key players in the pharmaceutical contract manufacturing market include Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), WuXi AppTec (China), WuXi Biologics (China), AbbVie Inc. (US), Catalent, Inc. (Novo Holdings) (US), Samsung Biologics (South Korea), Evonik (Germany), FUJIFILM Holding Corporation (Japan), Siegfried Holding AG (Switzerland), and Boehringer Ingelheim International GmbH (Germany). Other notable companies are Merck KGaA (Germany), Almac Group (UK), Charles River Laboratories (US), Asymchem Inc. (China), Vetter (Germany), and Alcami Corporation (US).

医薬品受託製造市場 - 2030年までの世界予測 ecosystem — pharmaceutical-contract-manufacturing-market-Ecosystem

Research Coverage

This research report categorizes the pharmaceutical contract manufacturing market, by service {drug development services, pharmaceutical manufacturing services [pharmaceutical API manufacturing services, pharmaceutical FDF manufacturing services (parenteral, tablet, capsule, oral liquid, semi-solid, other formulations), biologics manufacturing services (biologics API manufacturing services, biologics FDF manufacturing services)], packaging & labelling services, fill-finish services, other services}, molecule [small molecules (high-potency small molecules, oligonucleotide & synthetic peptides, radiopharmaceutical, and other molecules) large molecules (mAbs, CGT, ADC, vaccines, therapeutic peptides & proteins, and other large molecules)], end user (big pharmaceutical companies, small & mid-sized pharmaceutical companies, generic pharmaceutical companies, other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the pharmaceutical contract manufacturing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, acquisitions, and recent developments associated with the pharmaceutical contract manufacturing market.

Reasons to buy this report

The report will help market leaders and new entrants by providing them with closest approximations of the revenue numbers for the overall pharmaceutical contract manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better positioning their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (GLP-1 capacity crunch, increasing development and manufacturing of antibody drug conjugates, loss of exclusivity of blockbuster biologics, increasing complexity of injectable drug formats) restraints (pricing pressure on innovator drugs, growing penetration of generics and biosimilars, strict regulatory compliance, risk in advanced therapies pipeline), opportunities (Rising demand for cell and gene therapies, growing inclination toward one-stop-shop model, market expansion in emerging countries, booming radiopharmaceutical and nuclear medicine segment), and challenges (global trade instability and insourcing) influencing the growth of pharmaceutical contract development and manufacturing market.
Service Development/Innovation: Thorough investigation of recently launched services available in the pharmaceutical contract manufacturing market.
Market Development: Utilizing analysis of regional market trends, the study offers comprehensive knowledge on profitable markets.
Market Diversification: Comprehensive information on new services, underdeveloped areas, present developments, and pharmaceutical contract manufacturing sector investments is what market diversification is based on.
Competitive Assessment: A comprehensive evaluation of the market shares, growth strategies, and service offerings of prominent companies such as Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza (Switzerland), AbbVie Inc. (US), WuXi AppTec (China), and others in the pharmaceutical contract development and manufacturing market.

1 INTRODUCTION 42

1.1 STUDY OBJECTIVES 42

1.2 MARKET DEFINITION 42

1.3 STUDY SCOPE 42

1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 43

1.3.2 INCLUSIONS AND EXCLUSIONS 44

1.3.3 YEARS CONSIDERED 45

1.4 CURRENCY CONSIDERED 45

1.5 STAKEHOLDERS 45

1.6 SUMMARY OF CHANGES 46

2 RESEARCH METHODOLOGY 47

2.1 RESEARCH DATA 47

2.1.1 SECONDARY DATA 48

2.1.1.1 Key objectives of secondary research 48

2.1.1.2 Key data from secondary sources 49

2.1.2 PRIMARY DATA 49

2.1.2.1 Breakdown of primaries 50

2.1.2.2 Key objectives of primary research 50

2.2 MARKET SIZE ESTIMATION 51

2.2.1 GLOBAL MARKET ESTIMATION 51

2.2.1.1 Company revenue analysis (Bottom-up approach) 51

2.2.1.2 MnM repository analysis 53

2.2.1.3 Primary interviews 53

2.2.2 INSIGHTS FROM PRIMARY EXPERTS 54

2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 54

2.3 GROWTH RATE PROJECTIONS 55

2.4 DATA TRIANGULATION 57

2.5 RESEARCH ASSUMPTIONS 58

2.6 RESEARCH LIMITATIONS 59

2.7 RISK ANALYSIS 59

3 EXECUTIVE SUMMARY 60

3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS 64

3.1.1 PHARMACEUTICAL CONTRACT MANUFACTURERS 64

3.1.1.1 Capacity lock in for GLP-1 and biologics opportunities 64

3.1.1.2 Sterile fill-finish services 64

3.1.1.3 OSD differentiation and dual site sourcing 64

3.1.2 PHARMACEUTICAL COMPANIES 64

3.1.2.1 Own vs. outsourcing critical steps 64

3.1.2.2 Dual-source, multi-site supply resilience 65

3.1.3 STARTUPS AND INNOVATIVE BIOTECH FIRMS 65

3.1.3.1 Gene-to-IND platform 65

3.1.3.2 Clinical supply risk management 65

4 PREMIUM INSIGHTS 66

4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW 66

4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,

BY SERVICE AND COUNTRY, 2025 67

4.3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE 68

4.4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER 68

4.5 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GEOGRAPHIC

GROWTH OPPORTUNITIES 69

4.6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EMERGING VS.

DEVELOPED MARKETS 70

5 MARKET OVERVIEW 71

5.1 INTRODUCTION 71

5.2 MARKET DYNAMICS 71

5.2.1 DRIVERS 73

5.2.1.1 GLP-1 capacity crunch 73

5.2.1.2 Increasing development and manufacturing of antibody drug conjugates 74

5.2.1.3 Loss of exclusivity of blockbuster biologics 75

5.2.1.4 Increasing complexity of injectable drug formats 76

5.2.2 RESTRAINTS 77

5.2.2.1 Pricing pressure on innovator drugs 77

5.2.2.2 Growing penetration of generics and biosimilars 78

5.2.2.3 Strict regulatory compliance 78

5.2.2.4 Risk in advanced therapies pipeline 79

5.2.3 OPPORTUNITIES 79

5.2.3.1 Rising demand for cell and gene therapies 79

5.2.3.2 Growing inclination toward one-stop-shop model 82

5.2.3.3 Market expansion in emerging countries 82

5.2.3.4 Booming radiopharmaceutical and nuclear medicine segment 83

5.2.4 CHALLENGES 83

5.2.4.1 Global trade instability and insourcing 83

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 84

5.4 PRICING ANALYSIS 85

5.4.1 INDICATIVE PRICING ANALYSIS, BY SERVICE 85

5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION 86

5.4.3 COMPARISON OF CDMO PRICING MODELS 86

5.5 VALUE CHAIN ANALYSIS 87

5.6 SUPPLY CHAIN ANALYSIS 88

5.7 ECOSYSTEM ANALYSIS 91

5.7.1 MANUFACTURING SITE, EXPANSION, AND CAPEX TREND OF KEY CDMOS 93

5.8 INVESTMENT AND FUNDING SCENARIO 97

5.9 TECHNOLOGY ANALYSIS 98

5.9.1 KEY TECHNOLOGIES 98

5.9.1.1 Single-use bioprocessing systems 98

5.9.1.2 Continuous manufacturing 99

5.9.1.3 Advanced formulation technologies 99

5.9.2 COMPLEMENTARY TECHNOLOGIES 99

5.9.2.1 High-performance liquid chromatography 99

5.9.2.2 Mass spectrometry 100

5.9.2.3 Next-generation sequencing 101

5.9.2.4 Automation and robotics 101

5.9.2.5 Process analytical technology 101

5.9.3 ADJACENT TECHNOLOGIES 102

5.9.3.1 3D printing 102

5.9.3.2 Artificial intelligence and machine learning 102

5.10 PATENT ANALYSIS 103

5.11 KEY CONFERENCES AND EVENTS, 2025–2026 104

5.12 REGULATORY LANDSCAPE 106

5.12.1 REGULATORY SCENARIO 106

5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108

5.13 PORTER’S FIVE FORCES ANALYSIS 112

5.13.1 BARGAINING POWER OF SUPPLIERS 113

5.13.2 BARGAINING POWER OF BUYERS 113

5.13.3 THREAT OF NEW ENTRANTS 113

5.13.4 THREAT OF SUBSTITUTES 113

5.13.5 INTENSITY OF COMPETITIVE RIVALRY 113

5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 114

5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 114

5.14.2 BUYING CRITERIA 114

5.15 UNMET NEEDS OF END USERS 115

5.15.1 CAPACITY AND TIMELY ACCESS 115

5.15.2 COST EFFICIENCY AND FLEXIBILITY 116

5.15.3 END-TO-END INTEGRATED SERVICES 116

5.15.4 ADVANCED MODALITY EXPERTISE 116

5.15.5 QUALITY AND REGULATORY CONSISTENCY 116

5.16 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS 116

5.17 IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET 117

5.17.1 INTRODUCTION 117

5.17.2 MARKET POTENTIAL OF AI/GEN AI 117

5.17.3 AI USE CASES 118

5.17.4 KEY COMPANIES IMPLEMENTING AI/GEN AI 119

5.18 IMPACT OF 2025 US TARIFFS ON PHARMACEUTICAL CONTRACT

MANUFACTURING MARKET 120

5.18.1 INTRODUCTION 120

5.18.2 KEY TARIFF RATES 121

5.18.3 PRICE IMPACT ANALYSIS 122

5.18.4 IMPACT ON COUNTRY/REGION 122

5.18.4.1 US 122

5.18.4.2 Europe 123

5.18.4.3 Asia Pacific 123

5.18.4.3.1 India 124

5.18.5 IMPACT ON END-USE INDUSTRIES 124

6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE 126

6.1 INTRODUCTION 127

6.2 PHARMACEUTICAL MANUFACTURING SERVICES 127

6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES 131

6.2.1.1 Rising cases of patent expiry to fuel market 131

6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES 135

6.2.2.1 Parenteral manufacturing services 139

6.2.2.1.1 Increasing demand for specialized manufacturing capabilities to support growth 139

6.2.2.2 Tablet manufacturing services 142

6.2.2.2.1 Growing domestic production capacity in emerging markets to boost market 142

6.2.2.3 Capsule manufacturing services 146

6.2.2.3.1 Rising adoption in pharmaceutical, nutraceutical, and cosmetic applications to stimulate growth 146

6.2.2.4 Oral liquid manufacturing services 149

6.2.2.4.1 Growing preference for oral liquids over powders to fuel market 149

6.2.2.5 Semi-solid manufacturing services 153

6.2.2.5.1 Rising prevalence of skin infections and burns to foster growth 153

6.2.2.6 Other FDF manufacturing services 156

6.3 DRUG DEVELOPMENT SERVICES 160

6.3.1 INCREASING COST OF DRUG DISCOVERY AND DEVELOPMENT TO EXPEDITE GROWTH 160

6.4 BIOLOGICS MANUFACTURING SERVICES 163

6.4.1 BIOLOGICS API MANUFACTURING SERVICES 167

6.4.1.1 Rising investments in single-use production capacities to bolster growth 167

6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES 170

6.4.2.1 Growing demand for generic medicines and biologics to fuel market 170

6.5 PACKAGING & LABELING SERVICES 174

6.5.1 INCREASING COMPLEXITY AND STRINGENCY OF REGULATORY REQUIREMENTS FOR DRUG SAFETY AND EFFICACY TO FAVOR GROWTH 174

6.6 FILL-FINISH SERVICES 177

6.6.1 SURGE IN DEMAND FOR BIOLOGICS AND COMPLEX INJECTABLE THERAPIES TO BOOST MARKET 177

6.7 OTHER SERVICES 181

7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE 185

7.1 INTRODUCTION 186

7.2 SMALL MOLECULES 186

7.2.1 HIGH-POTENCY SMALL MOLECULES 190

7.2.1.1 Increasing adoption of high-potency small molecules for treating oncology, rare diseases, and other diseases to aid growth 190

7.2.2 OLIGONUCLEOTIDE & SYNTHETIC PEPTIDES 194

7.2.2.1 Growing focus on next-gen therapies to drive market 194

7.2.3 RADIOPHARMACEUTICAL MOLECULES 197

7.2.3.1 Advances in isotope production, radiolabeling chemistry, and theranostic approaches to boost market 197

7.2.4 OTHER SMALL MOLECULES 201

7.3 LARGE MOLECULES 204

7.3.1 MONOCLONAL ANTIBODIES 208

7.3.1.1 Rising use of mAbs in managing cancer, autoimmune disorders, and osteoporosis to spur growth 208

7.3.2 CELL & GENE THERAPIES 212

7.3.2.1 Emerging treatments for previously untreatable genetic and rare diseases to boost market 212

7.3.3 ANTIBODY DRUG CONJUGATES 215

7.3.3.1 Growing need for precision medicines to fuel market 215

7.3.4 VACCINES 219

7.3.4.1 Growing threat of infectious disease outbreaks to drive market 219

7.3.5 THERAPEUTIC PEPTIDES & PROTEINS 222

7.3.5.1 Increasing research in genomics to support growth 222

7.3.6 OTHER LARGE MOLECULES 225

8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER 229

8.1 INTRODUCTION 230

8.2 BIG PHARMACEUTICAL COMPANIES 230

8.2.1 PRICING PRESSURE IN PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO GROWTH 230

8.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES 234

8.3.1 NEED TO SAVE IN-HOUSE DRUG MANUFACTURING COST TO FOSTER GROWTH 234

8.4 GENERIC PHARMACEUTICAL COMPANIES 238

8.4.1 FAVORABLE GOVERNMENT SUPPORT FOR ADOPTION OF GENERIC DRUGS TO PROPEL MARKET 238

8.5 OTHER END USERS 241

9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION 245

9.1 INTRODUCTION 246

9.2 NORTH AMERICA 246

9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 247

9.2.2 US 253

9.2.2.1 High clinical trial and drug discovery activities to foster growth 253

9.2.3 CANADA 258

9.2.3.1 Favorable government support and increased focus on R&D activities to sustain growth 258

9.3 EUROPE 263

9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 263

9.3.2 GERMANY 269

9.3.2.1 Free drug-pricing policy and high pharmaceutical investments to speed up growth 269

9.3.3 UK 274

9.3.3.1 Favorable R&D funding scenario to augment growth 274

9.3.4 FRANCE 278

9.3.4.1 Booming life science research and growing generics market to drive market 278

9.3.5 ITALY 283

9.3.5.1 Rising commercial drug development and increasing life science R&D to favor growth 283

9.3.6 SWITZERLAND 287

9.3.6.1 Rapid growth as global pharmaceutical manufacturing hub to drive market 287

9.3.7 POLAND 292

9.3.7.1 Universal health coverage and advanced government-supported medical infrastructure to encourage growth 292

9.3.8 SPAIN 296

9.3.8.1 Growing pharmaceutical R&D expenditure and increasing outsourcing of trial phases to boost market 296

9.3.9 REST OF EUROPE 301

9.4 ASIA PACIFIC 305

9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 306

9.4.2 CHINA 312

9.4.2.1 Made in China 2025 initiative and high government drug development investments to aid growth 312

9.4.3 JAPAN 317

9.4.3.1 High geriatric population and advanced pharmaceutical research to augment growth 317

9.4.4 SOUTH KOREA 321

9.4.4.1 Increased biotech investments and developed pharma sector to propel market 321

9.4.5 INDIA 325

9.4.5.1 Favorable industrial environment and lower labor costs to drive market 325

9.4.6 AUSTRALIA 330

9.4.6.1 Strategic geographical location and stringent regulatory environment to foster growth 330

9.4.7 REST OF ASIA PACIFIC 334

9.5 LATIN AMERICA 338

9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 338

9.5.2 BRAZIL 344

9.5.2.1 Rapid patient enrolment and increased focus on advanced clinical trials to expedite growth 344

9.5.3 MEXICO 348

9.5.3.1 Surge in pharmaceutical goods export to promote growth 348

9.5.4 REST OF LATIN AMERICA 352

9.6 MIDDLE EAST 357

9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 357

9.6.2 GCC COUNTRIES 363

9.6.2.1 Kingdom of Saudi Arabia (KSA) 368

9.6.2.1.1 Increasing healthcare expenditure to aid growth 368

9.6.2.2 UAE 372

9.6.2.2.1 Strategic government healthcare initiatives and broader economic diversification plans to drive market 372

9.6.2.3 Rest of GCC countries 377

9.6.3 REST OF MIDDLE EAST 381

9.7 AFRICA 385

9.7.1 RISING PREVALENCE OF CHRONIC DISEASES TO FACILITATE GROWTH 385

9.7.2 MACROECONOMIC OUTLOOK OF AFRICA 385

10 COMPETITIVE LANDSCAPE 391

10.1 INTRODUCTION 391

10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 391

10.3 REVENUE SHARE ANALYSIS, 2020–2024 394

10.4 MARKET SHARE ANALYSIS, 2024 395

10.5 COMPANY VALUATION AND FINANCIAL METRICS 398

10.6 BRAND/SERVICE COMPARISON 399

10.6.1 THERMO FISHER SCIENTIFIC INC. 400

10.6.2 LONZA 400

10.6.3 WUXI BIOLOGICS AND WUXI APPTEC 400

10.6.4 CATALENT, INC. 400

10.6.5 SAMSUNG BIOLOGICS 400

10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 401

10.7.1 STARS 401

10.7.2 EMERGING LEADERS 401

10.7.3 PERVASIVE PLAYERS 401

10.7.4 PARTICIPANTS 401

10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 403

10.7.5.1 Company footprint 403

10.7.5.2 Region footprint 404

10.7.5.3 Service footprint 405

10.7.5.4 Molecule footprint 406

10.8 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 408

10.8.1 PROGRESSIVE COMPANIES 408

10.8.2 RESPONSIVE COMPANIES 408

10.8.3 DYNAMIC COMPANIES 408

10.8.4 STARTING BLOCKS 408

10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 410

10.8.5.1 Detailed list of key startups/SMEs 410

10.8.5.2 Competitive benchmarking of key startups/SMEs 411

10.9 COMPETITIVE SCENARIO 412

10.9.1 SERVICE LAUNCHES 412

10.9.2 DEALS 413

10.9.3 EXPANSIONS 416

11 COMPANY PROFILES 419

11.1 KEY PLAYERS 419

11.1.1 THERMO FISHER SCIENTIFIC INC. 419

11.1.1.1 Business overview 419

11.1.1.2 Services offered 421

11.1.1.3 Recent developments 422

11.1.1.3.1 Service launches 422

11.1.1.3.2 Deals 422

11.1.1.4 MnM view 423

11.1.1.4.1 Key strengths 423

11.1.1.4.2 Strategic choices 423

11.1.1.4.3 Weaknesses and competitive threats 423

11.1.2 LONZA 424

11.1.2.1 Business overview 424

11.1.2.2 Services offered 426

11.1.2.3 Recent developments 427

11.1.2.3.1 Deals 427

11.1.2.3.2 Expansions 429

11.1.2.4 MnM view 431

11.1.2.4.1 Key strengths 431

11.1.2.4.2 Strategic choices 431

11.1.2.4.3 Weaknesses and competitive threats 431

11.1.3 CATALENT, INC. 432

11.1.3.1 Business overview 432

11.1.3.2 Services offered 433

11.1.3.3 Recent developments 435

11.1.3.3.1 Service launches 435

11.1.3.3.2 Deals 436

11.1.3.3.3 Expansions 437

11.1.3.4 MnM view 439

11.1.3.4.1 Key strengths 439

11.1.3.4.2 Strategic choices 439

11.1.3.4.3 Weaknesses and competitive threats 439

11.1.4 WUXI APPTEC 440

11.1.4.1 Business overview 440

11.1.4.2 Services offered 441

11.1.4.3 Recent developments 442

11.1.4.3.1 Deals 442

11.1.4.3.2 Expansions 442

11.1.4.4 MnM view 443

11.1.4.4.1 Key strengths 443

11.1.4.4.2 Strategic choices 443

11.1.4.4.3 Weaknesses and competitive threats 443

11.1.5 WUXI BIOLOGICS 444

11.1.5.1 Business overview 444

11.1.5.2 Services offered 445

11.1.5.3 Recent developments 446

11.1.5.3.1 Service launches 446

11.1.5.3.2 Deals 446

11.1.5.3.3 Expansions 447

11.1.5.3.4 Other developments 447

11.1.6 SAMSUNG BIOLOGICS 448

11.1.6.1 Business overview 448

11.1.6.2 Services offered 450

11.1.6.3 Recent developments 450

11.1.6.3.1 Service launches 450

11.1.6.3.2 Deals 451

11.1.6.3.3 Expansions 452

11.1.7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 453

11.1.7.1 Business overview 453

11.1.7.2 Services offered 455

11.1.7.3 Recent developments 455

11.1.7.3.1 Deals 455

11.1.7.3.2 Expansions 456

11.1.7.3.3 Other developments 456

11.1.8 EVONIK 457

11.1.8.1 Business overview 457

11.1.8.2 Services offered 458

11.1.8.3 Recent developments 459

11.1.8.3.1 Deals 459

11.1.8.3.2 Expansions 459

11.1.9 FUJIFILM HOLDINGS CORPORATION 460

11.1.9.1 Business overview 460

11.1.9.2 Services offered 461

11.1.9.3 Recent developments 463

11.1.9.3.1 Deals 463

11.1.9.3.2 Expansions 464

11.1.10 ABBVIE INC. 466

11.1.10.1 Business overview 466

11.1.10.2 Services offered 467

11.1.10.3 Recent developments 468

11.1.10.3.1 Deals 468

11.1.10.3.2 Expansions 469

11.1.11 SIEGFRIED HOLDING AG 470

11.1.11.1 Business overview 470

11.1.11.2 Services offered 471

11.1.11.3 Recent developments 472

11.1.11.3.1 Deals 472

11.1.11.3.2 Expansions 473

11.1.12 MERCK KGAA 474

11.1.12.1 Business overview 474

11.1.12.2 Services offered 476

11.1.12.3 Recent developments 476

11.1.12.3.1 Deals 476

11.1.12.3.2 Expansions 477

11.1.13 ALMAC GROUP 478

11.1.13.1 Business overview 478

11.1.13.2 Services offered 479

11.1.13.3 Recent developments 480

11.1.13.3.1 Deals 480

11.1.13.3.2 Expansions 481

11.1.14 CHARLES RIVER LABORATORIES 482

11.1.14.1 Business overview 482

11.1.14.2 Services offered 483

11.1.14.3 Recent developments 483

11.1.14.3.1 Deals 483

11.1.14.3.2 Expansions 484

11.1.15 ASYMCHEM INC. 485

11.1.15.1 Business overview 485

11.1.15.2 Services offered 486

11.1.15.3 Recent developments 487

11.1.15.3.1 Deals 487

11.1.15.3.2 Expansions 487

11.1.16 VETTER 488

11.1.16.1 Business overview 488

11.1.16.2 Services offered 489

11.1.16.3 Recent developments 489

11.1.16.3.1 Service launches 489

11.1.16.3.2 Deals 490

11.1.16.3.3 Expansions 490

11.1.17 ALCAMI CORPORATION 491

11.1.17.1 Business overview 491

11.1.17.2 Services offered 491

11.1.17.3 Recent developments 492

11.1.17.3.1 Deals 492

11.1.17.3.2 Expansions 492

11.1.18 EUROFINS SCIENTIFIC 493

11.1.18.1 Business overview 493

11.1.18.2 Services offered 494

11.1.18.3 Recent developments 495

11.1.18.3.1 Expansions 495

11.2 OTHER PLAYERS 496

11.2.1 PIRAMAL PHARMA SOLUTIONS 496

11.2.2 SYNGENE INTERNATIONAL LIMITED 497

11.2.3 CAMBREX CORPORATION 498

11.2.4 JUBILANT PHARMANOVA LIMITED 499

11.2.5 YUHAN CORPORATION 500

11.2.6 PIERRE FABRE LABORATORIES 501

11.2.7 PFIZER CENTREONE 502

11.2.8 DELPHARM 503

11.2.9 FRONTAGE LABS 504

11.2.10 SHARP SERVICES, LLC 505

11.2.11 GRAND RIVER ASEPTIC MANUFACTURING 506

11.2.12 RECIPHARM AB 507

11.2.13 PCI PHARMA SERVICES 508

11.2.14 CURIA GLOBAL, INC. 509

11.2.15 SIMTRA BIOPHARMA SOLUTIONS 510

11.2.16 PORTON 510

11.2.17 MABPLEX INTERNATIONAL CO. LTD. 511

11.2.18 CELLARES 512

12 APPENDIX 513

12.1 DISCUSSION GUIDE 513

12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 517

12.3 CUSTOMIZATION OPTIONS 519

12.4 RELATED REPORTS 520

12.5 AUTHOR DETAILS 521

LIST OF TABLES

TABLE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET:

INCLUSIONS AND EXCLUSIONS 44

TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 57

TABLE 3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RISK ANALYSIS 59

TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET:

IMPACT ANALYSIS OF MARKET DYNAMICS 72

TABLE 5 GLP-1 PIPELINE, EXPECTED LAUNCH BY 2030 73

TABLE 6 ADC PIPELINE, EXPECTED LAUNCH BY 2030 74

TABLE 7 IMPENDING AND ONGOING PATENT EXPIRIES OF BLOCKBUSTER

BIOLOGICS, 2023–2035 75

TABLE 8 LIST OF RECENTLY APPROVED INJECTABLES, 2022–2024 77

TABLE 9 CELL & GENE THERAPY-SPECIFIC CDMO EXPANSIONS, 2023–2025 80

TABLE 10 CELL & GENE THERAPY PIPELINE, EXPECTED LAUNCH BY 2030 80

TABLE 11 INDICATIVE PRICING ANALYSIS, BY SERVICE 85

TABLE 12 INDICATIVE PRICING ANALYSIS, BY REGION 86

TABLE 13 PRICING MODELS FOR CDMO SERVICES 86

TABLE 14 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET:

ROLE OF COMPANIES IN SUPPLY CHAIN 89

TABLE 15 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET:

ROLE OF COMPANIES IN ECOSYSTEM 91

TABLE 16 MANUFACTURING SITES OF KEY CDMOS 93

TABLE 17 LIST OF SITE EXPANSIONS FOR KEY CDMOS, 2023–2025 95

TABLE 18 CAPEX FOR SELECTED PUBLICLY LISTED KEY CDMOS, 2021–2024 (USD MILLION) 96

TABLE 19 NUMBER OF PATENTS FILED IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2014–2024 103

TABLE 20 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET:

KEY CONFERENCES AND EVENTS, 2025–2026 105

TABLE 21 REGULATORY SCENARIO, BY COUNTRY 106

TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 108

TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 109

TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 110

TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 111

TABLE 26 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 111

TABLE 27 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 111

TABLE 28 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET:

PORTER’S FIVE FORCES ANALYSIS 112

TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PHARMACEUTICAL CONTRACT MANUFACTURING SERVICES (%) 114

TABLE 30 BUYING CRITERIA FOR PHARMACEUTICAL CONTRACT MANUFACTURING,

BY END USER 115

TABLE 31 US-ADJUSTED RECIPROCAL TARIFF RATES 121

TABLE 32 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE,

2023–2030 (USD BILLION) 127

TABLE 33 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,

2023–2030 (USD BILLION) 128

TABLE 34 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION,

2023–2030 (USD BILLION) 128

TABLE 35 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD BILLION) 129

TABLE 36 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 129

TABLE 37 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD BILLION) 130

TABLE 38 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD BILLION) 130

TABLE 39 MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,

BY REGION, 2023–2030 (USD BILLION) 131

TABLE 40 GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD BILLION) 131

TABLE 41 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION,

2023–2030(USD BILLION) 132

TABLE 42 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030(USD BILLION) 132

TABLE 43 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030(USD BILLION) 133

TABLE 44 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030(USD BILLION) 133

TABLE 45 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030(USD BILLION) 134

TABLE 46 MIDDLE EAST: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,

BY REGION, 2023–2030(USD BILLION) 134

TABLE 47 GCC COUNTRIES: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030(USD BILLION) 134

TABLE 48 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE,

2023–2030(USD BILLION) 135

TABLE 49 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION,

2023–2030(USD BILLION) 136

TABLE 50 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030(USD BILLION) 136

TABLE 51 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030(USD BILLION) 137

TABLE 52 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030(USD BILLION) 137

TABLE 53 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030(USD BILLION) 138

TABLE 54 MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,

BY REGION, 2023–2030(USD BILLION) 138

TABLE 55 GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030(USD BILLION) 138

TABLE 56 PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION,

2023–2030 (USD BILLION) 139

TABLE 57 NORTH AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD BILLION) 140

TABLE 58 EUROPE: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD BILLION) 140

TABLE 59 ASIA PACIFIC: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 141

TABLE 60 LATIN AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 141

TABLE 61 MIDDLE EAST: PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 142

TABLE 62 GCC COUNTRIES: PARENTERAL MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD BILLION) 142

TABLE 63 TABLET MANUFACTURING SERVICES MARKET, BY REGION,

2023–2030 (USD BILLION) 143

TABLE 64 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD BILLION) 143

TABLE 65 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD BILLION) 144

TABLE 66 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD BILLION) 144

TABLE 67 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 145

TABLE 68 MIDDLE EAST: TABLET MANUFACTURING SERVICES MARKET, BY REGION,

2023–2030 (USD BILLION) 145

TABLE 69 GCC COUNTRIES: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 145

TABLE 70 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION,

2023–2030 (USD BILLION) 146

TABLE 71 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD BILLION) 147

TABLE 72 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD BILLION) 147

TABLE 73 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 148

TABLE 74 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 148

TABLE 75 MIDDLE EAST: CAPSULE MANUFACTURING SERVICES MARKET, BY REGION,

2023–2030 (USD BILLION) 149

TABLE 76 GCC COUNTRIES: CAPSULE MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD BILLION) 149

TABLE 77 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION,

2023–2030 (USD BILLION) 150

TABLE 78 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD BILLION) 150

TABLE 79 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD BILLION) 151

TABLE 80 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 151

TABLE 81 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 152

TABLE 82 MIDDLE EAST: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 152

TABLE 83 GCC COUNTRIES: ORAL LIQUID MANUFACTURING SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD BILLION) 152

TABLE 84 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION,

2023–2030 (USD BILLION) 153

TABLE 85 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 154

TABLE 86 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD BILLION) 154

TABLE 87 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 155

TABLE 88 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 155

TABLE 89 MIDDLE EAST: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 156

TABLE 90 GCC COUNTRIES: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 156

TABLE 91 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION,

2023–2030 (USD BILLION) 157

TABLE 92 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 157

TABLE 93 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD BILLION) 158

TABLE 94 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 158

TABLE 95 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 159

TABLE 96 MIDDLE EAST: OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION) 159

TABLE 97 GCC COUNTRIES: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 159

TABLE 98 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD BILLION) 160

TABLE 99 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 161

TABLE 100 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 161

TABLE 101 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 162

TABLE 102 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 162

TABLE 103 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD BILLION) 162

TABLE 104 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 163

TABLE 105 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION) 164

TABLE 106 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION) 164

TABLE 107 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 164

TABLE 108 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 165

TABLE 109 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 165

TABLE 110 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 166

TABLE 111 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION) 166

TABLE 112 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION) 166

TABLE 113 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION) 167

TABLE 114 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET